Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG)
Phase of Trial: Phase IV
Latest Information Update: 06 Feb 2017
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 31 Jan 2017 Status changed from active, no longer recruiting to completed.
- 19 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, as reported by ClinicalTrials.gov.
- 19 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jan 2015, as reported by ClinicalTrials.gov.